travel manag build momentum coupl area
recent host investor meet manag team baxter investor
remain concern compani gener growth medic deliveri
busi year manag good job detail lever get
believ inde hit number compani discuss excit
gener inject busi molecul contribut significantli
top-lin come year note solid legisl momentum
push home dialysi could buoy franchis go forward though
includ model still focu organ larger deal
seem unlik given hefti ebitda price would pay continu
like manag team refin portfolio strong balanc sheet reiter
ow rate increas pt
confid deliveri outlook investor skeptic
gener cc growth medic deliveri busi full year follow
soft perform howev manag walk us number dynam
allow get said done inde believ
segment deliv figur investor fixat moment
bullish pharma beyond year renal busi although
short-term headwind form cyclo brevibloc tune year
latter manag note number compel molecul work
expect add hundr million dollar top-lin
respect renal plenti momentum base domest busi
potenti legisl chang boost outlook though model
 still card like smaller deal manag note hefti price
roughli ebitda would pay deal signific scale mean
unlik near term howev remain focu organ
expect smaller transact futur believ add signific valu
type deal given manufactur prowess sizeabl global distribut
stock share rebound nice far year
still trade reason ev/ebitda multipl compar favor
larg cap name compani strong balanc sheet difficult
bet consequ continu like name reiter ow rate
price pressur gener competit deal execut
ebitda
assum net debt s/o
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
recent host investor meet manag team baxter attend
compani evp cfo jay saccaro vice-president ir clare trachtman quit impress
manag thorough understand busi even question bax
pension liabil clear messag stori
surprisingli first question investor surround medic deliveri
busi follow result manag provid full year guidanc call
growth fear unattain compani good job explain dynam
franchis overal believ achiev growth rate year
starter much easier comp second half year make base
easier grow second given two-way wireless featur new pump carri initi
softwar issu custom push order back half last year
manag state line-of-sight system purchas
also tailwind final manag note strong interest product
intern expect contribut least bp growth year collect
believ factor allow deliv growth rate medic deliveri
year show progress end expect help lift stock even
fortun investor seem appear comfort manag view
year outlook medic deliveri soon turn convers rest
busi clear optim gener inject busi manag anticip
dexm gener worth revenu year go forward compani plan
launch anoth molecul year hospit base alon categori
manag believ product gener annual revenu similar dexm
longer term compani still anoth molecul develop coupl expect
deliv annual sale remaind like level least
sale like manag reiter expect worth gener
inject sale within pharma busi although lost brevi sale year roughli
continu cyclo headwind expect weigh pharma busi
aggreg year believ categori return growth next year beyond
addit manag note renal busi continu perform well
optimist outlook note compani mention regulatori
momentum behind home dialysi ever seen hope legisl
come push treatment modal current home dialysi repres
esrd patient pd hhd call key administr
washington move number closer eventu reason view
home dialysi perform often three time week provid in-
center therapi outcom frequent dialysi often much better thrice weekli
treatment make intuit sens peopl without esrd kidney function time
remov toxin wast dialysi better legisl push toward home
dialysi would clearli posit though includ anyth estim
compani bullish theranova technolog play in-cent market
mimic natur kidney function much better tradit product lastli manag
point ou market longer term opportun renal busi includ japan
eventu china time latter unknown point combin
newer market signific room differenti technolog theranova
make us believ grow franchis mid-singl digit year come
part busi appear well investor attent meet
turn compani strong balanc sheet manag indic continu look
page
type asset perspect note valuat risen
meaning deal size would cost roughli ebitda includ premium
get transact done make ton sens rather anticip
smaller deal go forward rather one big transform one certainli
ok given larg global distribut footprint push smaller product larger audienc
hesit specul baxter may go deal execut littl
med tech space would realli surpris us ceo almeida proven courag deal
make covidien day
lastli move price target previous roll
ev/ebitda target multipl unchang forward ebitda
middl year
page
million
sale
market administr
revenu report
percent sale
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
